NCT Number: NCT05884398
Phase: PHASE3
Trial Summary: The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: LIBERTAS
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives